ARRY - Gilead Buys More Galapagos Callon Acquires Carrizo; Confirming XBI And XOP ETF Strategies
Gilead invests in Galapagos, confirms further consolidation in the Biotech/Pharma Space
Look, I am no genius when it comes to biotech. The whole drug approval process requires an extra lifetime to get the hang of. That said, the economics of finding biotech drugs to fill a sales pipeline makes complete sense to me. Companies like Gilead (GILD), or Bristol Myers (BMY) buying Celgene (CELG), or even Pfizer (PFE) with its recent acquisition of Array BioPharma (ARRY), need the new product because the old product is going off patent. There is a seemingly never-ending supply of